Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VentureHHS: Government Fund Would Invest In Firms Developing Medical Countermeasures

This article was originally published in The Pink Sheet Daily

Executive Summary

While BARDA focuses on products, the new fund would support the viability of developers, NIAID Director Fauci says

You may also be interested in...



Bioterror Investor Fund Would Get $20 Mil. Ante Under Senate Appropriations Bill

Funding for the Cures Acceleration Network would also be increased, to $40 million in fiscal 2013, under the legislation marked up by the Appropriations subcommittee; the full committee will work on the bill June 14.

FDA Emergency Use Power Could Expand Under Bill Moving To House Floor

FDA could get the power to issue an Emergency Use Authorization before a pandemic or other emergency, according to legislation reauthorizing the Pandemic and All-Hazards Preparedness Act.

FDA Emergency Use Power Could Expand Under Bill Moving To House Floor

FDA could get the power to issue an Emergency Use Authorization before a pandemic or other emergency, according to legislation reauthorizing the Pandemic and All-Hazards Preparedness Act.

Related Content

Topics

UsernamePublicRestriction

Register

PS071062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel